Azacitidine in high-risk MDS patients. A "real life" experience from a single center

被引：1
|
作者：
Greco, R. [1 ]
Riva, M. [1 ]
Ravano, E. [1 ]
Molteni, A. [1 ]
Morra, E. [1 ]
机构：
[1] Osped Niguarda Ca Granda, Ematol, Milan, Italy
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70346-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-299
引用
收藏
页码：S157 / S157
页数：1
相关论文
共 50 条
  • [1] Azacitidine Improves Outcome in Patients with MDS and AML with High Risk Cytogenetics - a Single Center Experience
    Murthy, Vidhya
    Kapuge, Nilupulee
    Kartsios, Charalampos
    Ewing, Joanne
    Xenou, Evgenia
    Kaparou, Maria
    Shereef, Elmoamly
    Nikolousis, Emmanouil
    BLOOD, 2018, 132
  • [2] Azacitidine therapy in high-risk myelodysplastic syndromes (MDS): A single centre experience
    Improta, S.
    Gagliardi, A.
    Villa, M. R.
    Della Cioppa, P.
    Esposito, M.
    Izzo, G. Nitrato
    Mastrullo, L.
    LEUKEMIA RESEARCH, 2013, 37 : S152 - S152
  • [3] SALVAGE VENETOCLAX COMBINATION THERAPY IN PATIENTS WITH AML TRANSFORMATION AFTER AZACITIDINE THERAPY FAILURE FOR HIGH-RISK MDS - SINGLE-CENTER EXPERIENCE
    Minarik, L.
    Stopka, T.
    Zemanova, Z.
    Sotakova, S.
    Jonasova, A.
    LEUKEMIA RESEARCH, 2023, 128
  • [4] Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience
    Ozbalak, Murat
    Cetiner, Mustafa
    Bekoz, Huseyin
    Atesoglu, Elif Birtas
    Ar, Cem
    Salihoglu, Ayse
    Tuzuner, Nukhet
    Ferhanoglu, Burhan
    HEMATOLOGICAL ONCOLOGY, 2012, 30 (02) : 76 - 81
  • [5] LUSPATERCEPT IN THE TREATMENT OF MDS PATIENTS. A SINGLE CENTER EXPERIENCE
    Bouchla, A.
    Thomopoulos, T.
    Loucari, C.
    Apostolopoulou, C.
    Vryttia, P.
    Zorba, A.
    Gkondopoulos, K.
    Papageorgiou, S.
    Pappa, V.
    LEUKEMIA RESEARCH, 2023, 128
  • [6] REAL LIFE DATA ON AZACITIDINE THERAPY FOR INTERMEDIATE-2/HIGH-RISK MDS, AML WITH MDS-RELATED CHANGES AND CMML-2: AN UPDATE OF A SINGLE CENTRE EXPERIENCE
    Cametti, G.
    Ceretto, C.
    Grasso, A.
    Paparo, C.
    Godio, L.
    Artoni, P.
    HAEMATOLOGICA, 2021, 106 (10) : 173 - 173
  • [7] Cytogenetic peripheral blood monitoring in azacitidine treated patients with high-risk MDS/sAML: A monocentric real-world experience
    Braulke, Friederike
    Schweighofer, Adrian
    Schanz, Julie
    Shirneshan, Katayoon
    Ganster, Christina
    Pollock-Kopp, Beatrix
    Leha, Andreas
    Haase, Detlef
    LEUKEMIA RESEARCH, 2023, 124
  • [8] Casirivimab-Imdevimab in high-risk patients with COVID-19: a single center "Real-life" experience
    Marc, Hildebrand
    Jean-Christophe, Goffard
    Bruno, Couturier
    Benoit, Vokaer
    Frederic, Vandergheynst
    ACTA CLINICA BELGICA, 2021, 76 : 63 - 63
  • [9] THE MDS/MPN PATIENTS TREATED WITH 5-AZACITIDINE: A CLINICAL REAL LIFE EXPERIENCE
    Riva, M.
    Molteni, A.
    Borin, L.
    Bernardi, M.
    Pellizzari, A.
    Freyrie, A.
    Della Porta, M.
    Nichelatti, M.
    Ravano, E.
    Quaresmini, G.
    Mariotti, J.
    Caramazza, D.
    Ubezio, M.
    Guarco, S.
    Gigli, F.
    Greco, R.
    Cairoli, R.
    HAEMATOLOGICA, 2015, 100 : 725 - 725
  • [10] Invasive Fungal Infections in Patients with High-Risk MDS and AML Treated with Azacitidine
    Pomares, Helena
    Arnan, Montserrat
    Sanchez-Ortega, Isabel
    Sureda, Anna
    Duarte, Rafael F.
    BLOOD, 2015, 126 (23)
12345